{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'of discontinuation of the study treatment, the investigations scheduled for the EOT visit should', 'be performed.', 'If a patient withdraws consent for further study treatment during the treatment phase, the', 'patient should still be followed for structured follow-up (i.e. documentation of the 3-monthly', 'visits). If a patient withdraws consent for further participation in the study, follow-up', 'assessments will be discontinued.', 'Should a patient decide to withdraw, all efforts will be made to complete and report the', 'observations as thoroughly as possible.', 'In any case, the eCRF section entitled \"End of Study\" must be completed.', '5.6 Study Discontinuation', 'The whole study may be discontinued at the discretion of the Sponsor in the event of any of', 'the following:', 'Medical or ethical reasons affecting the continued performance of the study', 'Difficulties in the recruitment of patients', 'Occurrence of AEs unknown to date in respect of their nature, severity and duration or', 'the unexpected incidence of known AE', 'Further the study will be discontinued if:', 'Favorable opinion and/or approval is revoked', 'A necessary adaption of the maximum insurance sum in not possible', 'Confidential', 'Page 41 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '6', 'Trial Procedures and Assessments', '6.1', 'Trial Procedures', 'Study procedures and their timing are summarized in the Schedule of Trial Activities in', 'Section 2.3. Individual trial procedures are described in detail below.', 'Adherence to the trial design requirements, including those specified in the Schedule', 'of Trial Activities in Section 2.3 is essential and required for trial conduct. Nevertheless,', 'it may be necessary to perform these procedures at unscheduled time points if deemed', 'clinically necessary by the investigator.', 'The investigator is responsible for ensuring that procedures are conducted by', 'appropriately qualified (by education, training and experience) staff.', 'All screening evaluations must be completed and reviewed to confirm that potential trial', 'participants meet all eligibility criteria. The investigator will maintain a screening log to', 'record details of all participants screened and to confirm eligibility or record reasons for', 'screening failure, as applicable.', 'Additional evaluations/testing may be deemed necessary by the Investigator or the', 'Sponsor for reasons related to participant safety. In some cases, such', 'evaluation/testing may be potentially sensitive in nature (e.g. HIV, Hepatitis C), and', 'thus local regulations may require that additional informed consent be obtained from', 'the participant. In these cases, such evaluations/testing will be performed in', 'accordance with those regulations.', \"Procedures conducted as part of the participant's routine clinical management (e.g.,\", 'blood count) and obtained before signing of ICF may be utilized for screening or', 'baseline purposes provided the procedure met the protocol-specified criteria and were', 'performed within the time frame defined in the Schedule of Trial Activities (Section 2.3).', '6.1.1 Administrative Procedures', '6.1.1.1 Informed Consent', 'The Investigator must obtain documented consent from each potential participant prior to', 'participating in the clinical trial and before any study related procedures are performed. If there', \"are changes to a participant's status during the study (e.g. health requirements) the\", 'investigator must ensure appropriate consent is in place.', '6.1.1.2 General Informed Consent', \"Consent must be documented by the participant's dated signature on a consent form along\", 'with the dated signature of the person conducting the consent discussion.', 'A copy of the signed and dated consent form should be given to the participant before', 'participation in the trial.', 'The initial informed consent form, any subsequent revised written informed consent form and', \"any written information provided to the participant must receive the IRB/IEC's\", 'Confidential', 'Page 42 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'approval/favourable opinion in advance of use. The participant or his/her legally acceptable', 'representative should be informed in a timely manner if new information becomes available', \"that may be relevant to the participant's willingness to continue participation in the trial. The\", 'communication of this information will be provided and documented via a revised consent form', \"or addendum to the original consent form that captures the participant's dated signature or by\", \"the participant's legally acceptable representative's dated signature.\", 'Specifics about the trial and the trial population will be added to the consent form template at', 'the protocol level.', 'The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations', 'and Sponsor requirements.', '6.1.1.3 Inclusion/Exclusion Criteria', 'All inclusion and exclusion criteria (Section 5.1.1 and Section 5.1.2) will be reviewed by the', 'investigator or qualified designee to ensure that the participant qualifies for this trial.', '6.1.1.4 Medical History', 'A medical history will be obtained by the investigator or qualified designee. Medical history will', 'include all active conditions, and any condition diagnosed within the prior 10 years that are', \"considered to be clinically significant by the Investigator. Details regarding the patient's\", 'colorectal cancer for which the participant has enrolled in this study will be recorded separately', 'and not listed as medical history.', '6.1.1.5 Prior and Concomitant Medications Review', '6.1.1.5.1 Prior Medications', 'The investigator or qualified designee will review prior medication use, including any protocol-', 'specified washout requirement, and record prior medication taken by the participant within 28', 'days before starting the trial. Prior anti-cancer treatment, if allowed by the inclusion/exclusion', \"criteria, for the patient's colorectal cancer will be recorded separately and not listed as a prior\", 'medication.', '6.1.1.5.2 Concomitant Medications', 'The investigator or qualified designee will record relevant medication, if any, taken by the', 'participant during the trial. All medications related to reportable SAEs should be recorded as', 'defined in Section 6.2.', 'Confidential', 'Page 43 of 79']\n\n###\n\n", "completion": "END"}